

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Webcasted presentation to take place at 1:10pm ET

DENVER, CO / November 30, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.

Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to Questions@EmergingGrowth.com.

Management’s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this [LINK](#) or visit the Company’s website.

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on [EmergingGrowth.com](http://www.EmergingGrowth.com) and on the Emerging Growth YouTube Channel, <http://www.YouTube.com/EmergingGrowthConference>.

Management will also host one-on-one investor meetings after the conference. To request a virtual 1x1 meeting with the Aytu management team, please contact your respective Emerging Growth Conference representative or email the Company’s investor relations team at AYTU@lythampartners.com.

About Aytu BioPharma, Inc.

Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the

investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

Contacts for Investors:

Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com

Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/810896/aytu-biopharma-to-present-on-the-emerging-growth-conference-on-december-7-2023>